The Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) has scheduled a meeting on Friday May 12, 2023. During the meeting, the committee will review Biologic license application (BLA 125781) submitted by Sarepta Therapeutics, Inc. for delandistrogene moxeparvovec with the requested indication for the treatment of ambulatory patients with Duchenne Muscular Dystrophy (DMD) with a confirmed mutation in the DMD gene.